Pharma intelligence in minutes,
not meetings.
FDA approvals, trials, patents, pipelines — into clear decisions, fast.
8,200+ drugs · 147,000+ trials · 1,300+ patent landscapes · Updated weekly.
The questions that take an hour elsewhere
Answered in one click. Or search your own above.
What's inside
Live data. FDA, ClinicalTrials.gov, SEC, Orange Book, Purple Book — refreshed weekly.
Approval timeline, mechanism, trials, global patent portfolio, revenue arc
Pipeline by phase, drug-by-drug revenue, head-to-head competitor maps
Phase, status, sponsor, recruiting filter, condition search
PDUFA calendar, patent cliff with revenue arcs, density heatmap
Orange Book + global patent family, expiry by country, with editorial commentary
Get the next Brief in your inbox — free
Every drug has multiple stories. Most never get told. One brief every week. No spam.
Archive lives at /briefs/. Unsubscribe anytime.
Latest briefs
Deep dives into drugs, targets, and competitive dynamics.
Entyvio: The Only IBD Drug That Stays in the Gut
Eleven years after approval, Entyvio remains the only IBD drug that acts only in the gut — and two large pharma programs have failed trying to replicate it.
T-Cell Engagers: The Off-the-Shelf Alternative to CAR-T
One arm grabs the cancer cell. The other grabs a T-cell. The bispecific forces them together.
IGF-1R: 20 Years of Cancer Failures, Then a $2 Billion Eye Drug
Pfizer, Amgen, Lilly, Merck, and Astellas all failed at IGF-1R in cancer. Then a shelved Roche antibody became the only effective treatment for thyroid eye disease. Same receptor, completely different biology.
Recent FDA Approvals
View allMost Active (5yr)
View allUpcoming FDA Decisions
Full calendarBlockbuster drugs
Browse all drugs →Pro tools
Pre-built analyses. The slow research is already done.
Every upcoming FDA decision, color-coded by urgency. AdCom meetings integrated.
Humira -73%, Revlimid -81%, Stelara -43% — actual SEC revenue declines, not Medicare proxies.
Targets with approved drugs but thin pipeline. Where the next opportunity lives.
Trial density across 19 therapeutic areas, visual at a glance.
All the pharma data. No sales calls.
Free tier gives you search and detail pages. Pro unlocks exports, filters, alerts, watchlists, and the dashboards above — $99/month or $990/year.
A fraction of the cost of enterprise intelligence platforms. No procurement. No 6-month sales cycle. No 5-figure annual contracts.